Effectiveness and safety of different administration routes of medical cannabis or cannabinoids for chronic pain in adults: a systematic review and network meta-analysis with GRADE assessment
Abstract
BackgroundChronic pain lasting more than 3 months affects more than one billion people globally, ranking as the third most prevalent health burden, after cardiovascular diseases and malignancies. This study aimed to evaluate the effectiveness and safety of medical cannabis or cannabinoids for chronic pain in adults, with prespecified subgroup analyses stratified by pain etiology and administration route to support precision pain management.MethodsA systematic literature search was conducted across PubMed, EMBASE, and the Cochrane Library from each database’s inception to 15 March 2025. The certainty of evidence was assessed with the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) framework. The focused outcomes were pain relief, sleep quality, physical and emotional functioning, anxiety, depression, and adverse events.ResultsTwenty-eight studies were involved. Compared to placebo, palmitoylethanolamide (PEA) (SMD = −0.82, 95% CI:−1.36 to −0.29; very low) and tetrahydrocannabinol (THC) (SMD = −0.41, 95% CI:−0.74 to −0.07; low) provided pain relief, and a THC/cannabidiol (CBD) combination significantly improved sleep quality (SMD = −0.43, 95% CI:−0.62 to −0.24; moderate). Regarding safety outcomes, compared to placebo, THC (RR = 3.55, 95% CI: 2.21 to 5.68; low) and THC/CBD (RR = 2.70, 95% CI: 1.60 to 4.53; high) had a relatively high rate of dizziness, and THC (RR = 2.72, 95% CI: 1.76 to 4.22; low) and THC/CBD (RR = 2.92, 95% CI: 1.74 to 4.90; high) had a significant risk of somnolence. THC/CBD elevated nausea risk (RR = 1.81, 95% CI: 1.26 to 2.60; high), while THC increased dry mouth incidence (RR = 3.14, 95% CI: 1.75 to 5.63; moderate). Additionally, compared with placebo for pain relief, CBD demonstrated the greatest effectiveness for cancer-related pain (SMD = −1.62, 95% CI:−2.03 to −1.21), whereas PEA showed optimal effectiveness in non-cancer-related pain (SMD = −0.82, 95% CI:−1.31 to −0.33).ConclusionThis study suggested that medical cannabis or cannabinoids might have certain efficacy for adult chronic pain. PEA and THC provided pain relief, while the THC/CBD combination showed a potential benefit for sleep quality improvement. THC was associated with increased risks of dizziness, somnolence, and dry mouth, and THC/CBD was associated with dizziness, somnolence, and nausea. Subgroup analyses suggested that treatment response might vary by pain etiology and administration route. Given that the evidence certainty is mainly low to very low, the research conclusion still requires a large sample and high-quality randomized controlled trials (RCTs) to be verified.Systematic Review Registrationhttps://osf.io/h56g9, Unique Identifier: 10.17605/OSF.IO/H56G9.
Related
- Comparative effectiveness of exercise and self-management interventions delivered through different modes of digital support on pain and patient-reported physical function in people with knee osteoarthritis: a systematic review and network meta-analysis of randomised controlled trials
- Effectiveness of digital self-assessment and support tools for improving maternal and child health in Africa: a protocol of a systematic review
- Potential reverse spin bias of cannabinoids versus pharmaceutical analgesics for pain treatment: a systematic review based critical interpretive synthesis of meta-analyses.
- Effectiveness of Contemporary Invisalign® Clear Aligners for Derotation and Deep Bite Correction of Different Degrees of Severity in Adolescents and Adults: A Retrospective Clinical Study
- Pre-TAS Evaluation of mass drug administration effectiveness on lymphatic filariasis elimination and study of Immunological response in elephantiasis patients in Osun State, Nigeria
BibTeX
@article{zhao2026effectiveness,
title = {{Effectiveness and safety of different administration routes of medical cannabis or cannabinoids for chronic pain in adults: a systematic review and network meta-analysis with GRADE assessment}},
author = {Min-Hua Zhao and Hua-Ling Jiang and Zi-Jing Yu and Chao Zhang and Yi-Fan Zhao and Lin Zhao and Lin-Kang Zhao and Fu-Qiang Yin and Yan Fu and Yu-Zhen Li},
journal = {Frontiers in Pharmacology},
year = {2026},
month = nov,
doi = {10.3389/fphar.2026.1895235},
url = {https://www.frontiersin.org/articles/10.3389/fphar.2026.1895235},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Effectiveness and safety of different administration routes of medical cannabis or cannabinoids for chronic pain in adults: a systematic review and network meta-analysis with GRADE assessment
AU - Min-Hua Zhao
AU - Hua-Ling Jiang
AU - Zi-Jing Yu
AU - Chao Zhang
AU - Yi-Fan Zhao
AU - Lin Zhao
AU - Lin-Kang Zhao
AU - Fu-Qiang Yin
AU - Yan Fu
AU - Yu-Zhen Li
PY - 2026
DA - 2026/11/03
JO - Frontiers in Pharmacology
DO - 10.3389/fphar.2026.1895235
UR - https://www.frontiersin.org/articles/10.3389/fphar.2026.1895235
AB - BackgroundChronic pain lasting more than 3 months affects more than one billion people globally, ranking as the third most prevalent health burden, after cardiovascular diseases and malignancies. This study aimed to evaluate the effectiveness and safety of medical cannabis or cannabinoids for chronic pain in adults, with prespecified subgroup analyses stratified by pain etiology and administration route to support precision pain management.MethodsA systematic literature search was conducted across PubMed, EMBASE, and the Cochrane Library from each database’s inception to 15 March 2025. The certainty of evidence was assessed with the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) framework. The focused outcomes were pain relief, sleep quality, physical and emotional functioning, anxiety, depression, and adverse events.ResultsTwenty-eight studies were involved. Compared to placebo, palmitoylethanolamide (PEA) (SMD = −0.82, 95% CI:−1.36 to −0.29; very low) and tetrahydrocannabinol (THC) (SMD = −0.41, 95% CI:−0.74 to −0.07; low) provided pain relief, and a THC/cannabidiol (CBD) combination significantly improved sleep quality (SMD = −0.43, 95% CI:−0.62 to −0.24; moderate). Regarding safety outcomes, compared to placebo, THC (RR = 3.55, 95% CI: 2.21 to 5.68; low) and THC/CBD (RR = 2.70, 95% CI: 1.60 to 4.53; high) had a relatively high rate of dizziness, and THC (RR = 2.72, 95% CI: 1.76 to 4.22; low) and THC/CBD (RR = 2.92, 95% CI: 1.74 to 4.90; high) had a significant risk of somnolence. THC/CBD elevated nausea risk (RR = 1.81, 95% CI: 1.26 to 2.60; high), while THC increased dry mouth incidence (RR = 3.14, 95% CI: 1.75 to 5.63; moderate). Additionally, compared with placebo for pain relief, CBD demonstrated the greatest effectiveness for cancer-related pain (SMD = −1.62, 95% CI:−2.03 to −1.21), whereas PEA showed optimal effectiveness in non-cancer-related pain (SMD = −0.82, 95% CI:−1.31 to −0.33).ConclusionThis study suggested that medical cannabis or cannabinoids might have certain efficacy for adult chronic pain. PEA and THC provided pain relief, while the THC/CBD combination showed a potential benefit for sleep quality improvement. THC was associated with increased risks of dizziness, somnolence, and dry mouth, and THC/CBD was associated with dizziness, somnolence, and nausea. Subgroup analyses suggested that treatment response might vary by pain etiology and administration route. Given that the evidence certainty is mainly low to very low, the research conclusion still requires a large sample and high-quality randomized controlled trials (RCTs) to be verified.Systematic Review Registrationhttps://osf.io/h56g9, Unique Identifier: 10.17605/OSF.IO/H56G9.
SN - 1663-9812
ER -